AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
- Conditions
- Melanoma
- Interventions
- Drug: CP-675,206
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT00431275
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT00430729
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kingdom, United Kingdom
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
- Conditions
- Schizophrenia
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00428350
- Locations
- 🇨🇳
Research SIte, Wuhan, Hubei, China
🇨🇳Research Site, Beijing, China
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
- Conditions
- Gastric Ulcer
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00428701
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
🇺🇸Research SIte, Newark, Delaware, United States
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients
- Conditions
- GERD
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00427635
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
- Conditions
- Hypercholesterolaemia
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00427960
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
🇬🇧Research SIte, Slough, United Kingdom
Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PlaceboDrug: Roflumilast
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 743
- Registration Number
- NCT00424268
- Locations
- 🇬🇧
Altana Pharma/Nycomed Investigational Site, Yaxley, United Kingdom
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00423332
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
- Conditions
- Affective Psychosis, BipolarDepression, BipolarManic-Depressive PsychosisPsychoses, Manic-Depressive
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00422214
- Locations
- 🇺🇸
Research Site, South Kirkland, Washington, United States
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
- Conditions
- Manic StateAffective Psychosis, BipolarManic DisorderManic-Depressive PsychosisManiaPsychoses, Manic-Depressive
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 447
- Registration Number
- NCT00422123
- Locations
- 🇺🇸
Research Sitew, Fort Lauderdale, Florida, United States
🇺🇸Research Site, Bellevue, Washington, United States